

To: Funda Bozkurt <[REDACTED]>
Cc: Thomas Klemm <[REDACTED]>; Ian Salters <[REDACTED]>
Subject: FW: Client OTC derivatives trading with CIB [I]

Classification: **For internal use only**

As regards the process:

1. Please see population attached.
2. Opt Up process mapped out already (I have sent the information to cover this)
3. Remove the delta process as WM clients are being fully onboarded in GM
4. We will not be creating separate KOP's;
5. Brexit requirements:
 - Remediate KYC for WM & IWP clients to meet CIB standards
 - Resend new ADL to letter to all clients (when redraft agreed)
 - Understand any further needs (e.g. London Terms of Business)
 - Clarify if Natural Persons can be moved to FFT, London have agreed to unwind risk when required.

Can I suggest we close this point and then open a new one based on our present plan of action.

Thomas –welcome your thoughts?

Regards

Ian

From: Funda Bozkurt
Sent: Friday, February 15, 2019 9:52 AM
To: Victoria Bruce <[REDACTED]>; Thomas Klemm <[REDACTED]>; Kimberly Hart <[REDACTED]>; Puzant Merdinian <[REDACTED]>; Steven Mattus <[REDACTED]>; Olivier Poncet <[REDACTED]>; Ian Salters <[REDACTED]>; Andrea DeMar <[REDACTED]>; Bill King <[REDACTED]>; Jeffrey Roth <[REDACTED]>
Subject: RE: Client OTC derivatives trading with CIB [I]

Classification: **For internal use only**

Please see below for the SII entered in Dec 2018. The due date is 04- June – 2019. The item is part of NFRC . Ian Salters is the IRM, Thomas Klemm is the MGT.

[REDACTED] - SII - Over the counter products executed through GM platforms